drugset / Trial / NCT00005025

Gene Therapy in Treating Women With Refractory or Relapsed Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

NCT00005025

Treatment

Summary

RATIONALE: Gene therapy may make the body build an immune response to kill tumor cells. PURPOSE: Phase II trial to study the effectiveness of gene therapy in treating women who have refractory or relapsed ovarian epithelial cancer, fallopian tube cancer, or peritoneal cancer.

Timeline

Start
2000-06
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ganciclovir Small molecule Intravenous
Subject herpes simplex thymidine kinase Unknown Other